DL2

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Solid TumorLocally Advanced Breast Cancer

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

1

Fludara

Sanofi

Preclinical

22

DATROWAY

Daiichi Sankyo

Preclinical

13

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

34

DL2

Sun Pharma Advanced Research Company Limited

Phase 2

15

Navmi

SSummit Therapeutics

Preclinical

16

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

17

Ifinatamab Deruxtecan

Daiichi Sankyo

Preclinical

18

Tulmimetostat

Novartis

Preclinical

19

Carboplatin AUC-5

Merck & Co.

Preclinical

110

MHB036C

MMinghui Pharmaceutical (Hangzhou) Ltd

Preclinical

1Show 30 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Extensive-stage Small-cell Lung Cancer1 trial

A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer

Active, not recruiting·BioNTech·Phase 2·NCT06449209·110 enrolled

Solid Tumor1 trial

A Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors

Recruiting·Sun Pharma Advanced Research Company Limited·Phase 1·NCT07042100·177 enrolled

Locally Advanced Breast Cancer1 trial

A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer

Active, not recruiting·BioNTech·Phase 2·NCT06449222·83 enrolled

Details

Drug Info

Related News